Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTHFD2 | P13995 | 2/20 | 0.44 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 10/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14596957 | 0.86 | HTR1A (0.50) | MCHR1 | |
| SCHEMBL5452542 | 0.82 | MEN1 (0.48) | MTHFD2PDE4BLMNAMAPK1MEN1 | |
| SCHEMBL5452408 | 0.82 | MEN1 (0.59) | MTHFD2SLC6A7LMNAMAPK1MEN1 | |
| SCHEMBL5450910 | 0.82 | MEN1 (0.48) | MTHFD2PDE4BPDE4DLMNAMAPK1 | |
| SCHEMBL5449763 | 0.81 | MEN1 (0.48) | MTHFD2SLC6A7LMNAMAPK1MEN1 | |
| SCHEMBL5458790 | 0.80 | TMEM97 (0.48) | MTHFD2LMNAMAPK1MEN1POLB | |
| SCHEMBL5459678 | 0.80 | LMNA (0.48) | MTHFD2SLC6A7LMNAMAPK1MEN1 | |
| SCHEMBL5447987 | 0.78 | TMEM97 (0.46) | MTHFD2 | |
| SCHEMBL22411192 | 0.78 | MTHFD2 (0.43) | MTHFD2LMNAMAPK1MEN1KMT2A | |
| SCHEMBL5454925 | 0.77 | MTHFD2 (0.44) | MTHFD2LMNAMAPK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010526-A1 | Therapeutic isoquinoline compounds | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
| US-20070010526-A1 | Therapeutic isoquinoline compounds | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
| US-20070010526-A1 | Therapeutic isoquinoline compounds | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
| EP-1451172-A1 | THERAPEUTIC ISOQUINOLINE COMPOUNDS | AstraZeneca AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003037887-A1 | THERAPEUTIC ISOQUINOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010526-A1 | Therapeutic isoquinoline compounds | HTR1B, HTR1D, HTR1A | MTHFD2 4243/4885SLC6A7 388/4885PDE4B 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.